Coronavirus Update: AstraZeneca To Develop Oxford’s Vaccine, Adaptive Trial Delivers Remdesivir's Good News

More Details From China's Negative Results In Lancet

AstraZeneca is to develop and distribute Oxford's COVID-19 vaccine candidate in collaboration with Vaccitech. Its developers believe it could be available as early as September.

AZ_Courtyard
AstraZeneca's new HQ is in Cambridge, but has a longstanding basic research relationship with the University of Oxford

AstraZeneca PLC has signed a partnership with the Oxford University-led group which has emerged as a potential frontrunner in the race to develop a vaccine for COVID-19.

The UK-headquartered company has agreed to oversee global development and distribution of the university’s recombinant adenovirus vaccine candidate, known as...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip